These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32014364)

  • 1. Treat-to-target in systemic lupus erythematosus: Where are we?
    Ríos-Garcés R; Espinosa G; van Vollenhoven R; Cervera R
    Eur J Intern Med; 2020 Apr; 74():29-34. PubMed ID: 32014364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting lupus low disease activity state and remission in SLE: novel insights.
    Gao D; Hao Y; Fan Y; Ji L; Zhang Z
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1083-1089. PubMed ID: 34392757
    [No Abstract]   [Full Text] [Related]  

  • 3. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).
    van Vollenhoven R; Voskuyl A; Bertsias G; Aranow C; Aringer M; Arnaud L; Askanase A; Balážová P; Bonfa E; Bootsma H; Boumpas D; Bruce I; Cervera R; Clarke A; Coney C; Costedoat-Chalumeau N; Czirják L; Derksen R; Doria A; Dörner T; Fischer-Betz R; Fritsch-Stork R; Gordon C; Graninger W; Györi N; Houssiau F; Isenberg D; Jacobsen S; Jayne D; Kuhn A; Le Guern V; Lerstrøm K; Levy R; Machado-Ribeiro F; Mariette X; Missaykeh J; Morand E; Mosca M; Inanc M; Navarra S; Neumann I; Olesinska M; Petri M; Rahman A; Rekvig OP; Rovensky J; Shoenfeld Y; Smolen J; Tincani A; Urowitz M; van Leeuw B; Vasconcelos C; Voss A; Werth VP; Zakharova H; Zoma A; Schneider M; Ward M
    Ann Rheum Dis; 2017 Mar; 76(3):554-561. PubMed ID: 27884822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting DORIS Remission and LLDAS in SLE: A Review.
    Parra Sánchez AR; van Vollenhoven RF; Morand EF; Bruce IN; Kandane-Rathnayake R; Weiss G; Tummala R; Al-Mossawi H; Sorrentino A
    Rheumatol Ther; 2023 Dec; 10(6):1459-1477. PubMed ID: 37798595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treat to target, remission and low disease activity in SLE.
    Morand EF; Mosca M
    Best Pract Res Clin Rheumatol; 2017 Jun; 31(3):342-350. PubMed ID: 29224676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treat to target in systemic lupus erythematosus].
    Mucke J; Düsing C; Chehab G; Schneider M
    Z Rheumatol; 2020 May; 79(4):351-358. PubMed ID: 32232548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis.
    Sun F; Zhang D; Wang H; Wang H; Liu Z; Geng S; Wang X; Li T; Wan W; Lu L; Teng X; Morel L; Ye S
    Clin Exp Rheumatol; 2022 Sep; 40(9):1733-1737. PubMed ID: 34874833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial.
    Mucke J; Kuss O; Brinks R; Schanze S; Schneider M
    Lupus Sci Med; 2021 Jul; 8(1):. PubMed ID: 34253649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
    Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
    Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
    Parodis I; Lindblom J; Barturen G; Ortega-Castro R; Cervera R; Pers JO; Genre F; Hiepe F; Gerosa M; Kovács L; De Langhe E; Piantoni S; Stummvoll G; Vasconcelos C; Vigone B; Witte T; ; Alarcón-Riquelme ME; Beretta L
    Ann Rheum Dis; 2024 Jun; 83(7):889-900. PubMed ID: 38373843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treat to target in systemic lupus erythematosus: a commentary.
    Ugarte-Gil MF; Burgos PI; Alarcón GS
    Clin Rheumatol; 2016 Aug; 35(8):1903-1907. PubMed ID: 27406378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force.
    Smith EMD; Aggarwal A; Ainsworth J; Al-Abadi E; Avcin T; Bortey L; Burnham J; Ciurtin C; Hedrich CM; Kamphuis S; Levy DM; Lewandowski LB; Maxwell N; Morand EF; Ozen S; Pain CE; Ravelli A; Saad Magalhaes C; Pilkington CA; Schonenberg-Meinema D; Scott C; Tullus K; Beresford MW;
    Ann Rheum Dis; 2023 Jun; 82(6):788-798. PubMed ID: 36627168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How can we define low disease activity in systemic lupus erythematosus?
    Tselios K; Gladman DD; Urowitz MB
    Semin Arthritis Rheum; 2019 Jun; 48(6):1035-1040. PubMed ID: 30415943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation.
    Parra Sánchez AR; Voskuyl AE; van Vollenhoven RF
    Nat Rev Rheumatol; 2022 Mar; 18(3):146-157. PubMed ID: 35039665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
    Pawlak-Buś K; Schmidt W; Leszczyński P
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
    Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treat-to-target in systemic lupus erythematosus: are we there yet?
    Mok CC
    Expert Rev Clin Pharmacol; 2016; 9(5):675-80. PubMed ID: 26809011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS).
    Smith EMD; Aggarwal A; Ainsworth J; Al-Abadi E; Avcin T; Bortey L; Burnham J; Ciurtin C; Hedrich CM; Kamphuis S; Lambert L; Levy DM; Lewandowski L; Maxwell N; Morand E; Ozen S; Pain CE; Ravelli A; Saad Magalhaes C; Pilkington C; Schonenberg-Meinema D; Scott C; Tullus K; Beresford MW;
    Clin Immunol; 2023 May; 250():109296. PubMed ID: 36934849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW; Bultink IE; Heslinga M; Voskuyl AE
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.